EMEA accepts Pharmion's Vidaza MAA

The EMEA accepted for review PHRM's MAA for Vidaza azacitidine to treat myelodysplastic syndromes (MDS). The nucleoside analog that causes DNA hypomethylation has Orphan Product designation from the E...